Answers are grounded in this paper and cite their sources.
B vitamins have long been investigated for their potential roles in pain modulation and neuropathy, yet their preclinical efficacy remains variably interpreted across models, endpoints, and treatment contexts. This narrative review synthesizes experimental evidence evaluating B-vitamin-based interventions in pain and neuropathy models, with attention to functional outcomes, dosing paradigms, and combination strategies. Fifty preclinical reports were summarized qualitatively, using author-reported results or estimates of maximal effects where appropriate. Individual vitamins and combination regimens improved selected mechanical, thermal, chemically evoked, operant, or neurofunctional outcomes, alongside negative and divergent findings. Studies of folic acid, thiamine derivatives, niacin, and nicotinamide riboside reported benefits in selected inflammatory, inherited, metabolic, and drug-induced models. These findings do not establish a consistently superior vitamin, a general advantage of B-complex over individual vitamins, or a uniform ranking of endpoint responsiveness. Selected drug–vitamin combinations showed potentiation or experimentally supported synergy, but such interactions cannot be inferred from cross-study percentage comparisons. Treatment timing, route, dose, nutritional context, and statistical reporting constrain interpretation; improved conduction or locomotion does not itself establish analgesia. Overall, the evidence supports further investigation of specific vitamin–model–regimen combinations, with explicit separation of prevention from treatment of established pain and attention to vitamin-specific safety. Clinical efficacy requires direct evaluation in appropriately defined patient populations.
No takes yet. Share an insight, caveat, or question.
Karaganis et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: